Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Not Yet Opened 11-04 16:00:00 EST

8.84

-0.06

-0.67%

盘后8.80

-0.04-0.45%

19:58 EST

High9.12	Low8.49	Vol4.57M
Open8.91	D1 Closing8.90	Amplitude7.13%
Mkt Cap542.49M	Tradable Cap387.14M	Total Shares61.37M
T/O40.45M	T/O Rate10.44%	Tradable Shares43.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":8.84,"timestamp":1730754000000,"preClose":8.9,"halted":0,"volume":4572882,"hourTrading":{"tag":"盘后","latestPrice":8.8,"preClose":8.84,"latestTime":"19:58 EST","volume":3893411,"amount":34416422.9382,"timestamp":1730768291941},"delay":0,"floatShares":43793634,"shares":61367509,"eps":-2.190008,"marketStatus":"Not Yet Opened","change":-0.06,"latestTime":"11-04 16:00:00 EST","open":8.91,"high":9.12,"low":8.485,"amount":40450534.368443996,"amplitude":0.071348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.190008,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730797200000},"marketStatusCode":0,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":8.9,"preHourTrading":{"tag":"盘前","latestPrice":8.91,"preClose":8.9,"latestTime":"09:29 EST","volume":916,"amount":7930.32267,"timestamp":1730730599999},"postHourTrading":{"tag":"盘后","latestPrice":8.8,"preClose":8.84,"latestTime":"19:58 EST","volume":3893411,"amount":34416422.9382,"timestamp":1730768291941},"volumeRatio":0.218045,"impliedVol":1.4365,"impliedVolPercentile":0.4263},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2479278022","title":"Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2479278022","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479278022?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:55","pubTimestamp":1730296504,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  have gained 76.8% over the past four weeks to close the last trading session at $9.37, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.67 indicates a potential upside of 67.2%.The average comprises six short-term price targets ranging from a low of $7 to a high of $20, with a standard deviation of $4.80. While the lowest estimate indicates a decline of 25.3% from the current price level, the most optimistic estimate points to an 113.5% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-believe-monte-135504403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2479428212","title":"Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479428212","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479428212?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:57","pubTimestamp":1730213832,"startTime":"0","endTime":"0","summary":"In a recent move in the Biotech industry, Monte Rosa Therapeutics  got into a great partnership with Swiss Novartis for up to $2.1 billion, lifting shares sky-high. The document deals with both parties' efforts to MRT-6160, a drug to treat ailments related to the immune system that is presently under phase I clinical trials.GuruFocus has detected 4 Warning Signs with GLUE.As part of the deal, Novartis is set to transfer $150 million to Monte Rosa to buy a worldwide license for MRT-6160 and other potential molecular glue degrader treatments. Beyond the $25 million upfront fee, Monte Rosa might be able to get additional payments for development, regulatory, and commercialization milestones, adding up to $2.1 billion every time the development enters Phase 2 studies. Royal has also included tiered royalties on the products to be sold in markets outside the United States of America.Novartis will take over clinical development and later commercialization starting in Phase 2, while Monte Ros","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fku.9wELr8JsloL3BHBTLw--~B/aD0yODU7dz00MjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/de028088c2fb810b95745f672ea59104","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fku.9wELr8JsloL3BHBTLw--~B/aD0yODU7dz00MjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/de028088c2fb810b95745f672ea59104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-shares-skyrocket-145712888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","GLUE","BK4539","BK4139"],"gpt_icon":0},{"id":"1159042407","title":"Stock Track | Monte Rosa Soars Over 140% on $2.25 Billion Novartis Licensing Deal for Novel Immune Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1159042407","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159042407?lang=en_us&edition=fundamental","pubTime":"2024-10-29 16:02","pubTimestamp":1730188938,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  skyrocketed over 140% in pre-market trading on October 29th, driven by a massive $2.25 billion global licensing agreement with pharmaceutical giant Novartis.Under the deal terms, Novartis gains exclusive worldwide rights to develop and commercialize Monte Rosa's lead drug program MRT-6160, an oral degrader of the VAV1 protein that regulates immune cell signaling. Novartis paid $150 million upfront and could pay up to $2.1 billion more in development, regulatory","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GLUE"],"gpt_icon":0},{"id":"1117889621","title":"Stock Track | Monte Rosa Soars on $2.25 Billion Novartis Deal for Novel Immune Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1117889621","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117889621?lang=en_us&edition=fundamental","pubTime":"2024-10-29 08:33","pubTimestamp":1730161983,"startTime":"0","endTime":"0","summary":"Shares of $Monte Rosa Therapeutics$, Inc.  skyrocketed 142% on October 28, 2024 after the clinical-stage biotech announced a massive $2.25 billion global licensing agreement with pharmaceutical giant Novartis. The deal gives Novartis exclusive worldwide rights to develop and commercialize Monte Rosa's lead program MRT-6160 and other VAV1-directed molecular glue degrader candidates for immune-mediated diseases.Under the terms, Novartis paid $150 million upfront to Monte Rosa and could pay up to $","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GLUE"],"gpt_icon":0},{"id":"2479517164","title":"Sector Update: Health Care Stocks Rise Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2479517164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479517164?lang=en_us&edition=fundamental","pubTime":"2024-10-29 03:59","pubTimestamp":1730145586,"startTime":"0","endTime":"0","summary":"Health care stocks edged up late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund  up 0.2%.The iShares Biotechnology ETF  gained 0.9%.In corporate news, PROCEPT BioRobotics  shares surged past 31% after the company released Q3 results that were above market expectations and raised its revenue outlook for 2024.Monte Rosa Therapeutics  shares soared 98%. The company said Monday that it signed a global development and commercialization license agreement with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160. Novartis shares rose 1.7%.Vera Therapeutics  shares jumped past 15% after the company disclosed long-term efficacy and favorable safety data from its phase 2b trial of kidney disease treatment candidate atacicept.Royal Philips  shares tumbled past 16%. The company cut its full-year comparable sales growth outlook amid a substantial drop in demand in China, while Q3 earnings were little changed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA","GLUE","BK4532","IE00BJT1NW94.SGD","IBB","BK4539","NVS","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009355771.USD","IE0002141913.USD","PHG","LU0211331839.USD","BK4585","BK4139","BK4578","BK4082","PRCT","BK4588","BK4581","BK4007","XLV","IE00BFTCPJ56.SGD","LU2324357040.USD"],"gpt_icon":1},{"id":"2479145312","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2479145312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479145312?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:37","pubTimestamp":1730140627,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  said Monday that it entered into a global development and commercialization license agreement with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160.Shares of Monte Rosa soared 140% as intraday trading volume catapulted to over 83.7 million from a daily average of more than 349,000.Autonomix Medical  said Monday three patients responded to its radio frequency pain management with femoral access in an ongoing clinical trial evaluating its potential to manage pain in pancreatic cancer patients without the use of opioids.Shares surged 71% as intraday trading volume climbed to more than 17.7 million, versus a daily average of over 20,000.Porch Group  said Monday the Texas Department of Insurance approved its application to form and license a new insurance reciprocal exchange.Shares jumped nearly 80%, with intraday trading volume at over 14.5 million compared with a daily average of more than 846,000.Price: 11.86, Change: +6.97, Percent Change","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4539","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4578","BK4532","IE00BJJMRZ35.SGD","AMIX","IE0002141913.USD","NVS","BK4585","IE00BFTCPJ56.SGD","IE0009355771.USD","GLUE","BK4082","LU0211331839.USD","PRCH","BK4139","BK4122","IE00B2B36J28.USD","BK4023","BK4007"],"gpt_icon":0},{"id":"2479643453","title":"Monte Rosa Therapeutics More Than Doubles on Novartis Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479643453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479643453?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:31","pubTimestamp":1730140260,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis.Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year.Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones.Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders.MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions.TD Cowen maintained its \"buy\" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2479493414","title":"Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2479493414","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479493414?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:27","pubTimestamp":1730140057,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.Initial d","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160717412/image_2160717412.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160717412/image_2160717412.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4730160-monte-rosa-novartis-deal-bolsters-mgd-platform-with-flush-of-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2479493458","title":"Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479493458","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479493458?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:10","pubTimestamp":1730139016,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/monte-rosa-therapeutics-novartis-molecular-glue-degraders-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","GLUE","IE00B4R5TH58.HKD","LU0211331839.USD","BK4532","BK4139","NVS","BK4588","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4539","IE0002141913.USD","BK4007","BK4578","BK4585"],"gpt_icon":0},{"id":"1161305361","title":"Stock Track | Monte Rosa Therapeutics Soars on $2.25 Billion Licensing Deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=1161305361","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161305361?lang=en_us&edition=fundamental","pubTime":"2024-10-29 00:30","pubTimestamp":1730133034,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  skyrocketed on Monday, surging 128.63% after the clinical-stage biotechnology company announced a global licensing agreement with pharmaceutical giant Novartis to develop a novel class of drugs called \"molecular glue degraders\".The agreement grants Novartis exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160, Monte Rosa's lead molecular glue degrader candidate, and other VAV1-directed degraders. MRT-6160 is currently in an ongoing Pha","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GLUE"],"gpt_icon":0},{"id":"2479431733","title":"BUZZ-U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack","url":"https://stock-news.laohu8.com/highlight/detail?id=2479431733","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479431733?lang=en_us&edition=fundamental","pubTime":"2024-10-29 00:28","pubTimestamp":1730132913,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake ShackEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nL4N3M418Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDW","AAPL","SMR","SONN","CCL","T","XOM","APA","NVDA","OXY","AMIX","MSFT","ABBV","HUT","EVOK","ADT","DDD","GLW","MARA","REAL","CCL.UK","SHAK","RVNC","HCTI","CNC","COP","NOVV","AMZN","GLUE","GEHC","NINE","L","SMX","CVX","FLR","RIOT","AZUL","AAL","PRCT","RBLX","BORR","MANU","QS","COIN","OKLO","BA","ON","HE","EYPT"],"gpt_icon":1},{"id":"2478435976","title":"Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2478435976","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478435976?lang=en_us&edition=fundamental","pubTime":"2024-10-28 23:50","pubTimestamp":1730130609,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $20 from $16 and keeps an Overweight rating on the shares after t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-raised-to-20-from-16-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-raised-to-20-from-16-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2478205482","title":"Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2478205482","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478205482?lang=en_us&edition=fundamental","pubTime":"2024-10-28 22:38","pubTimestamp":1730126314,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) has an average buy rating and a price target range of $7 to $20, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE"],"gpt_icon":0},{"id":"2478484477","title":"Monte Rosa Therapeutics Inc : Wedbush Raises Target Price to $15 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2478484477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478484477?lang=en_us&edition=fundamental","pubTime":"2024-10-28 22:26","pubTimestamp":1730125619,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nFWN3M41LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"2478484679","title":"PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2478484679","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478484679?lang=en_us&edition=fundamental","pubTime":"2024-10-28 22:14","pubTimestamp":1730124898,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41576730/procept-biorobotics-posts-strong-q3-earnings-joins-monte-rosa-therapeutics-eyepoint-pharmaceuticals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWL","WULF","GLUE","WRD","MNSO","VERA","PRCT","SERV","RVNC","MARA","PRTA","IBRX","EYPT","MSTR"],"gpt_icon":1},{"id":"2478489010","title":"BUZZ-Monte Rosa Therapeutics surges on licensing deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2478489010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478489010?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:58","pubTimestamp":1730123924,"startTime":"0","endTime":"0","summary":"** Shares of drug developer Monte Rosa Therapeutics    rise 37.22% to $6.84 ** Novartis    will pay GLUE $150 million upfront for a global license to develop, manufacture and sell some drug candidates","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2478548686","title":"Monte Rosa Therapeutics Shares up 30% After Co Signs Licensing Deal With Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2478548686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478548686?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:36","pubTimestamp":1730122589,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nFWN3M40RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2478488341","title":"Traders Eye Big Tech Earnings, Lifting US Equity Futures Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2478488341","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478488341?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:56","pubTimestamp":1730120186,"startTime":"0","endTime":"0","summary":"US equity futures were higher pre-bell Monday as traders looked ahead to this week's slate of earnings from major technology companies.The Dow Jones Industrial Average futures rose 0.4%, S&P 500 futur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"b2926d5f48e06867ce05b17b9e57e26f","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE",".SPX","GLW","GOOG","PHG",".DJI",".IXIC","MSFT","META","GOOGL","T","AMZN","AAPL","EQR","NVS"],"gpt_icon":1},{"id":"2478100483","title":"Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2478100483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478100483?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:49","pubTimestamp":1730119744,"startTime":"0","endTime":"0","summary":"Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis  will pay Monte Rosa Therapeutics    $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2478488742","title":"Why Is Monte Rosa Therapeutics Stock Surging On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2478488742","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478488742?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:46","pubTimestamp":1730119591,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc  stock is trading higher on Monday after the company announced a global exclusive development and commercialization license agreement with Novartis AG  to advance VAV1 MGDs, including MRT-6160.MRT-6160 is currently in an ongoing Phase 1, single ascending dose /multiple ascending dose  healthy volunteer study for immune-mediated conditions.Also Read: Monte Rosa Therapeutics’ AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 studies.Monte Rosa will co-fund any Phase 3 clinical development and share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S.Monte Rosa remains responsible for completing the ongoing Phase 1 c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/I2_HqG75E.zGHmXM_Effcg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/06b67cf2ce9901a167abbb87946fc277","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/I2_HqG75E.zGHmXM_Effcg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/06b67cf2ce9901a167abbb87946fc277"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-monte-rosa-therapeutics-stock-124631660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","GLUE","IE00B4R5TH58.HKD","LU0211331839.USD","BK4532","BK4139","NVS","BK4588","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4539","IE0002141913.USD","BK4007","BK4578","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.0675},{"period":"1month","weight":0.7367},{"period":"3month","weight":1.2667},{"period":"6month","weight":0.6806},{"period":"1year","weight":1.4693},{"period":"ytd","weight":0.5646}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.156816},{"month":2,"riseRate":0.666667,"avgChangeRate":0.04993},{"month":3,"riseRate":0.666667,"avgChangeRate":0.124226},{"month":4,"riseRate":0,"avgChangeRate":-0.295044},{"month":5,"riseRate":0.333333,"avgChangeRate":0.036693},{"month":6,"riseRate":0.333333,"avgChangeRate":0.028435},{"month":7,"riseRate":0.75,"avgChangeRate":0.0647},{"month":8,"riseRate":0.5,"avgChangeRate":0.131017},{"month":9,"riseRate":0.25,"avgChangeRate":-0.16729},{"month":10,"riseRate":0.75,"avgChangeRate":0.123042},{"month":11,"riseRate":0.25,"avgChangeRate":-0.074908},{"month":12,"riseRate":0.666667,"avgChangeRate":0.257702}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction